Opendata, web and dolomites

RheumArth SIGNED

New drug for the treatment of rheumatoid arthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RheumArth project word cloud

Explore the words cloud of the RheumArth project. It provides you a very rough idea of what is the project "RheumArth" about.

proof    foothold    time    damage    chronic    validate    trials    expectancy    variety    drugs    treatment    efficacy    market    decreased    self    autoimmune    amounting    synact    provider    1st    effectiveness    human    ensuing    iia    safety    foreseen    joints    therapeutic    modulating    generation    sme    volunteers    prepare    strategic    utmost    permanent    causing    small    company    30    preliminary    alone    area    disorder    renders    synthesized    incidence    surrounding    disease    threatening    supporting    million    candidate    unprecedent    ap1189    disability    position    innovation    treatments    molecule    people    therapies    tolerance    patients    life    validation    positioning    healthy    first    medium    45billion    patient    inflammatory    instrument    trail    context    ra    mechanisms    drug    profile    poc    anti    proved    clinical    compliance    tissues    showing    proportion    inflammation    combination    annual    immune    severe    rheumatoid    indication    arthritis    quality    mobilizing    acute    chemically    activation   

Project "RheumArth" data sheet

The following table provides information about the project.

Coordinator
SYNACT PHARMA APS 

Organization address
address: DRONNINGGARDS ALLE 136
city: HOLTE
postcode: 2840
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.synactpharma.com/sv/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNACT PHARMA APS DK (HOLTE) coordinator 50˙000.00

Map

 Project objective

Rheumatoid arthritis (RA) is a chronic autoimmune disorder causing inflammation and permanent damage in joints and surrounding tissues - leading to severe disability, decreased quality of life, and reduced life expectancy. The disease affects more than 6 million people with annual costs amounting to €45billion in the Europe (EU) alone. There is a wide range of drug therapies for RA, mobilizing a variety of anti-inflammatory and immune modulating effects. However, a significant proportion (30%) of the patients do not respond to current treatments, efficacy is often reduced over time and the incidence of side effects is high and can be severe and life threatening. AP1189 is new chemically-synthesized small molecule drug for the treatment of Rheumatoid arthritis (RA). Through specific activation of the patients’ self-anti-inflammatory mechanisms, our first drug candidate renders unprecedent combination of safety, effectiveness and patient compliance, without the side effects associated with current therapies. The clinical validation of our drug for RA - 1st indication (foreseen for the Innovation Project) - will not only open a large market within this therapeutic area, as it will allow Synact to set a market foothold in the chronic inflammatory disease market, supporting the company´s medium term strategic positioning as an unique provider of a new generation of anti-inflammatory drugs. AP1189 clinical validation is on-going with current Phase I clinical trials showing promising preliminary results – safety and tolerance was proved in healthy human volunteers. Next step in the development will be a Phase IIa Proof-Of-Concept (POC) trail to validate our drug´s efficacy profile in RA patients. In this context, the present Phase 1 will be of utmost importance to validate AP1189´s market position and potential in RA and prepare the large clinical validation aimed for in the ensuing SME Instrument Phase II project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHEUMARTH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RHEUMARTH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More